CHOICE-CLOSURE | Which Closure Device for TAVR is Better?

In patients who undergo transcatheter aortic valve replacement (TAVR) through transfemoral access, a closure device based on plug technology (MANTA VCD) is associated with a higher chance of access-related complications, but with shorter hemostasis time compared with a device with suture technology such as ProGlide VCD.

¿Cuál es el mejor tipo de dispositivo de cierre para el acceso del TAVI?

Nowadays, most patients undergo TAVR through transfemoral access. Percutaneous closure of the access bears multiple advantages for both patient and operator. However, there are several designs in the market, and it remains unclear which one is the most effective.

CHOICE-CLOSURE was a multicenter study in which patients scheduled for TAVR through femoral access were randomized to a device based on plug technology (Manta) vs. a device based on suture technology (ProGlide).

The protocol did not allow for an extra device when using Manta. In the case of ProGlide, two devices were used (at hours 10 and 14, respectively) and, if necessary, a small plug to help both PloGlide could be used (for example, AngioSeal).

The primary endpoint was major and minor access-related complications during the index hospitalization. The secondary endpoints included access-related bleeding, device failure to achieve hemostasis, and time to hemostasis.

About 516 patients were included and randomized, with a mean STS score of 4.1 ± 2.9% and 7.6% of associated peripheral vascular disease.


Read also: Suture-Based Percutaneous Closure vs. Plug for Large Arteriotomies.


The primary endpoint was reached in 19.4% of the population treated with Manta, and in 12% of those who received ProGlide (p = 0.029). Bleeding rates were better with ProGlide, while device efficacy was similar between both.

In terms of time to hemostasis, Manta was 3x faster (80 vs. 240 sec.; p < 0.001).

Conclusion

In patients who underwent transfemoral TAVR, the Manta device was linked to more vascular complications but reached hemostasis faster than two ProGlide. The time difference in relative terms seems a lot, but in absolute numbers it was barely over two minutes.

Original Title: Comparison of a Pure Plug-Based versus a Primary Suture-Based Vascular Closure Device Strategy for Transfemoral Transcatheter Aortic Valve Replacement: The CHOICE-CLOSURE Randomized Clinical Trial.

Reference: Mohamed Abdel-Wahab et al. Circulation. 2021 Nov 5. doi: 10.1161/CIRCULATIONAHA.121.057856. Online ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

 The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...